Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03298243 · ClinicalTrials.gov registry record · NA

Use of Sensory Substitution to Improve Arm Control After Stroke

A NA study of Stroke and Proprioceptive Disorders, sponsored by Marquette University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03298243: Recruiting NA study of Stroke and Proprioceptive Disorders, sponsored by Marquette University.

NCT03298243 is a NA study of Stroke and Proprioceptive Disorders that is actively recruiting participants, run by Marquette University. The registered enrollment target is 30 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03298243, a NA study of Stroke and Proprioceptive Disorders, is actively recruiting participants, sponsored by Marquette University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Supplementing or augmenting sensory information to those who have lost proprioception after stroke could help improve functional control of the arm. Thirty subjects will be recruited to a single site to evaluate the ability of supplemental kinesthetic feedback (a form of vibrotactile stimulation) to improve motor function. Participants will be tested in performing reaching movements as well as more functional tasks such as simulated drinking from a glass

Primary Outcome

orthogonal distance between target and hand position during reaching and stabilizing

Interventions

  • BEHAVIORAL Vibrotactile stimulation

Study Locations (1)

Wisconsin

  • Marquette University - Milwaukee

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-07-17
Est. Completion 2026-05-31
Phase NA
Marquette University

27 total trials

What NCT03298243 shows while recruiting

NCT03298243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Vibrotactile stimulation is the first listed.

NCT03298243 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03298243 about?

NCT03298243 is a clinical study titled "Use of Sensory Substitution to Improve Arm Control After Stroke". Supplementing or augmenting sensory information to those who have lost proprioception after stroke could help improve functional control of the arm. Thirty subjects will be recruited to a single site to evaluate the ability of supplemental kinesthetic feedback (a form of vibrotactile stimulation) to...

What is the current status of trial NCT03298243?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-07-17. Estimated completion is 2026-05-31.

What conditions does trial NCT03298243 study?

This clinical trial studies the following conditions: Stroke, Proprioceptive Disorders.

What interventions are being tested in trial NCT03298243?

The interventions under investigation include: Vibrotactile stimulation (BEHAVIORAL).

Who is sponsoring clinical trial NCT03298243?

This trial is sponsored by Marquette University, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03298243 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03298243's enrollment target sits among peer trials

30 301st of 454 higher than 137 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03298243, the US trial registry maintained by the National Library of Medicine. NCT03298243 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.